From Novo Nordisk Apr 2 2026 NICE has recommended Wegovy ® (semaglutide injection) 2.4 mg as the first GLP-1 RA to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (BMI ≥ 27 kg/m 2 ). This comes after the SELECT trial demonstrated that semaglutide 2.4 mg on top of standard of care reduced the risk for first occurrence of MACE by 20